Keep a close eye on Auxilium (AUXL). Check this out:
Shares of Auxilium Pharmaceuticals, Inc.(AUXL) soared after the company reported that the U.S. FDA has approved XIAFLEX(R)(collagenase clostridium histolyticum, or CCH), an in-office, biologic for the treatment of Peyronie's disease, a condition that involves the development of collagen plaque, or scar tissue, on the shaft of the male genital
The treatment will cost nearly $20,000 per patient, per year. Each injection of Xiaflex costs $3,300.
ZIOPHARM Oncology, Inc.(ZIOP) reported positive interim results from its ongoing Phase 1/2 study of Ad-RTS-IL-12, a novel DNA-based therapeutic candidate that is being evaluated with the oral activator, veledimex, in patients with advanced melanoma
Looking to deliver value for its stockholders in both the near and long term, and to improve the potential future growth for the company, Crown Equity Holdings Inc.(CRWE) is targeting the multi-billion dollar social networking community service market with its CRWE Network (CRWE-PR) project.
CRWE is currently developing a social networking service and phone app, CRWE Network (CRWE-PR), that is designed to target all the communities in every state of the United States.
Community of Encinitas, CA, visit CRWE Network Encinitas at http://encinitas.crwe-pr.com
Read full article at http://drstockpick.com/26673/stock-alerts/zio...